NEW YORK, Feb. 14 - Human Genome Sciences on Thursday said that bolstered R&D to develop new drugs together with shriveled revenue brought on by the end of the Human Gene Consortium caused net losses to widen in the fourth quarter.
NEW YORK, Feb. 14 - Human Genome Sciences on Thursday said that bolstered R&D to develop new drugs together with shriveled revenue brought on by the end of the Human Gene Consortium caused net losses to widen in the fourth quarter.